Endocrine Abstracts

Introduction and objectives: The cyclin-dependent kinases CDK4 and CDK6 are key regulators of the cell cycle entry, by phosphorylating the onco-suppressor retinoblastoma protein (pRb). CDK4/6 inhibitors (CDK4i) are already established as standard first-line treatment against advanced Estrogen Receptor-positive breast tumors, and have emerged as novel drugs to treat various pRb-proficient chemotherapy-resistant cancers. Presence of activating T172-phosphorylation of CDK4 in bre...